Drug development is never been easy. Reaching Phase 3 is never easy.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10210334/ Thirty‐seven new therapies—22 new chemical entities and 15 biologics—were approved by the FDA in 2022 across all therapeutic categories. 9 Five agents are active in the central nervous system (CNS) including one agent for relapsing multiple sclerosis, one treatment for amyotrophic lateral sclerosis, one anticonvulsant, and one therapy for the treatment of insomnia. One biological agent was directed at cerebral adrenoleukodystrophy to slow the progression of neurologic dysfunction. This is the smallest number of new drugs approved since 2016. There were no new treatments approved for AD in 2022. In 2021 and 2023, respectively, aducanumab and lecanemab received accelerated approval for the treatment of AD. Development for AD continues to be challenging with only these two drugs approved since 2003.
Prof. Wischik's work on Tau pathology began in 1985 in the laboratory of Sir Martin Roth, who was the first to correlate tangles with Alzheimer's dementia, and later with Sir Aaron Klug (Nobel Laureate) at Cambridge University.
For Genting to go up we need to wait for 1. FDA approval 2. Taurx planed list in Nasdaq with valuation of USD 15b for now fair value will be rm5 - 5.90 If FDA approves then may fly to 6-7! if listed in Nasdaq may fly between 6-9 depend on the valuation!
So far Current treatments help improve Alzheimer's symptoms, but no drug has yet been shown to slow disease progression. Lucidity is first drug that slow the AD progression!
Once approval is given or even just before some big pharma company may make an offer to JV or similar to manufacture market and distribute the product. What ever happens 2024 promises to be an exciting year. Remember markets look ahead. Those who sell early may miss out on ultimate gains.
Panel discussion today will further cement the outcome and success of the drug. New investors will pile in perhaps foreign flows when market opens later this afternoon. It will take time for news to filter through and ultimate possibilities will run for while. With 1qtr showing uptick things will look better.
RHB Research said TauRx could contribute RM1.3 billion-RM4.3 billion to Genting's financial year 2024 (FY24)-FY26 earnings, assuming a 10 per cent net margin.
KUALA LUMPUR: Merger and acquisition (M&A) of Genting Bhd's 20.3 per cent-owned research and development (R&D) associate TauRx Pharmaceuticals Ltd could allow for faster monetisation versus initial public offering (IPO), RHB Research said. The firm said while Genting did not comment on its strategy with regards to its TauRx stake, any option of value realisation or monetisation was definitely a positive after having invested in the firm since November 2012. "For TauRx to IPO, it would need to first commercialise its lead investigative oral drug, HMTM, in 2023 and undertake listing in 2024 or later.
"Conversely, we think M&A or in-licensing agreements may allow for earlier monetisation of Genting's stake, given that large pharmaceutical firms may have M&A interest in TauRx in order to possess the world's only effective Alzheimer's treatment.
"As a plus, M&A could allow TauRx to leverage on such firms' resources to expedite HMTM speed to market," it said in a note today. RHB Research said the HMTM drug would need to undergo 12 months of open-label trials – it could seek regulatory approvals for this Alzheimer's drug before the trial's conclusion.
RHB Research said TauRx could contribute RM1.3 billion-RM4.3 billion to Genting's financial year 2024 (FY24)-FY26 earnings, assuming a 10 per cent net margin. It could also fetch an upside of RM3.47-RM13.88 a share share based on 10x price to earnings ratio (P/E) on our base and bull cases for FY24 earnings," it said.
RHB said this could translates to hypothetical target price of RM9.84-RM20.25 for Genting.
Genting investors had been bitten too many times and are shy ow when it matters….2024 will be defining year unless boss unloads to invest in mars. I wonder what the price trend is with Taurx share price
Seems like traders are not keen on the idea of actually waiting for Taurx to bear fruit and contribute in actual QR dollars Probably only true investors are buying in
Today share price no bad, it let those purchase on 6 of March - 5.02 -4.82 (average transection price 4.90) to exit if they don't want to hold...........
KUALA LUMPUR (March 8): TauRx Pharmaceuticals Ltd, the 20%-owned associate of Genting Bhd, said new data show that its trial drug to combat Alzheimer's disease has “sustained benefits” across the disease spectrum from early to moderate dementia.
The new 24-month data from the third phase of the so-called LUCIDITY trial of hydromethylthionine mesylate (HMTM) showed “significantly” reduced disease progression in participants, TauRx said in a statement following a presentation at a conference in Portugal.
Genting’s target price could be raised to as high as RM9.40 under a blue sky scenario, where HMTM is approved and TauRx is valued at US$15 billion (RM70.3 billion) without discount, Maybank said.
This book is the result of the author's many years of experience and observation throughout his 26 years in the stockbroking industry. It was written for general public to learn to invest based on facts and not on fantasies or hearsay....
keyman
524 posts
Posted by keyman > 2024-03-07 22:11 | Report Abuse
今天taurx announce 的information. 之前在Agm的时候就mention过了。害我还以为会有什么特别的info. 弄的紧张兮兮的。看各位师父还气定神闲,像没什么一样,就知道我和各位师父们的差距。让你们见笑了🤭未来还请师父们多多指点我。谢谢各位师父🙏